Your browser doesn't support javascript.
loading
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Boum, Yap; Juan-Giner, Aitana; Hitchings, Matt; Soumah, Aboubacar; Strecker, Thomas; Sadjo, Mariama; Cuthbertson, Hannah; Hayes, Peter; Tchaton, Marie; Jemmy, Jean-Paul; Clarck, Carolyn; King, Deborah; Faga, Elisabetta Maria; Becker, Stephan; Halis, Bassam; Gunnstein, Norheim; Carroll, Miles; Røttingen, John-Arne; Kondé, Mandy Kader; Doumbia, Moise; Henao-Restrepo, Ana-Maria; Kieny, Marie-Paule; Cisse, Mohamed; Draguez, Bertrand; Grais, Rebecca F.
Afiliación
  • Boum Y; Epicentre, Yaoundé, Cameroon.
  • Juan-Giner A; Epicentre, Paris, France.
  • Hitchings M; Center for Communicable Disease Dynamics and Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
  • Soumah A; Epicentre, Paris, France.
  • Strecker T; Institute of Virology, Philipps University, Marburg, Germany.
  • Sadjo M; Centre Hospital-Universitaire de Donka, Conakry, Guinea.
  • Cuthbertson H; Public Health England, National Infection Service, Porton Down, UK.
  • Hayes P; Division of Medicine, Department of Infectious Diseases, Imperial College London, UK.
  • Tchaton M; Epicentre, Paris, France.
  • Jemmy JP; Médecins Sans Frontières-Operational Center Belgium, Brussels, Belgium.
  • Clarck C; Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.
  • King D; Division of Medicine, Department of Infectious Diseases, Imperial College London, UK.
  • Faga EM; Médecins Sans Frontières-Operational Center Belgium, Brussels, Belgium.
  • Becker S; Institute of Virology, Philipps University, Marburg, Germany.
  • Halis B; Public Health England, National Infection Service, Porton Down, UK.
  • Gunnstein N; Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Carroll M; Public Health England, National Infection Service, Porton Down, UK.
  • Røttingen JA; Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway; Department of Health and Society, University of Oslo, Norway; Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA; Coalition for Epidemic Preparedness Innovati
  • Kondé MK; Center of Excellence for Training, Research On Malaria & Priority Diseases In Guinea, Conakry, Guinea.
  • Doumbia M; World Health Organization, Geneva, Switzerland.
  • Henao-Restrepo AM; World Health Organization, Geneva, Switzerland.
  • Kieny MP; World Health Organization, Geneva, Switzerland.
  • Cisse M; Centre Hospital-Universitaire de Donka, Conakry, Guinea.
  • Draguez B; Médecins Sans Frontières-Operational Center Belgium, Brussels, Belgium.
  • Grais RF; Epicentre, Paris, France. Electronic address: Rebecca.grais@epicentre.msf.org.
Vaccine ; 38(31): 4877-4884, 2020 06 26.
Article en En | MEDLINE | ID: mdl-32499066
BACKGROUND: As part of a Phase III trial with the Ebola vaccine rVSVΔG-ZEBOV-GP in Guinea, we invited frontline workers (FLWs) to participate in a sub-study to provide additional information on the immunogenicity of the vaccine. METHODS: We conducted an open-label, non-randomized, single-arm immunogenicity evaluation of one dose of rVSVΔG-ZEBOV-GP among healthy FLWs in Guinea. FLWs who refused vaccination were offered to participate as a control group. We followed participants for 84 days with a subset followed-up for 180 days. The primary endpoint was immune response, as measured by ELISA for ZEBOV-glycoprotein-specific antibodies (ELISA-GP) at 28 days. We also conducted neutralization, whole virion ELISA and enzyme-linked immunospot (ELISPOT) assay for cellular response. RESULTS: A total of 1172 participants received one dose of vaccine and were followed-up for 84 days, among them 114 participants were followed-up for 180 days. Additionally, 99 participants were included in the control group and followed up for 180 days. Overall, 86.4% (95% CI 84.1-88.4) of vaccinated participants seroresponded at 28 days post-vaccination (ELISA- GP) with 65% of these seroresponding at 14 days post-vaccination. Among those who seroresponded at 28 days, 90.7% (95% CI 82.0-95.4) were still seropositive at 180 days. The proportion of seropositivity in the unvaccinated group was 0.0% (95% CI 0.0-3.8) at 28 days and 5.4% (95% CI 2.1-13.1) at 180 days post-vaccination. We found weak correlation between ELISA-GP and neutralization at baseline but significant pairwise correlation at 28 days post-vaccination. Among samples analysed for cellular response, only 1 (2.2%) exhibited responses towards the Zaire Ebola glycoprotein (Ebola GP ≥ 10) at baseline, 10 (13.5%) at day 28 post-vaccination and 27 (48.2%) at Day 180. CONCLUSIONS: We found one dose of rVSVΔG-ZEBOV-GP to be highly immunogenic at 28- and 180-days post vaccination among frontline workers in Guinea. We also found a cellular response that increased with time.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fiebre Hemorrágica Ebola / Vacunas contra el Virus del Ébola / Ebolavirus Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: Africa Idioma: En Revista: Vaccine Año: 2020 Tipo del documento: Article País de afiliación: Camerún Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fiebre Hemorrágica Ebola / Vacunas contra el Virus del Ébola / Ebolavirus Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: Africa Idioma: En Revista: Vaccine Año: 2020 Tipo del documento: Article País de afiliación: Camerún Pais de publicación: Países Bajos